Dapagliflozin vs Ertugliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT00528372 · Phase 3 · completed
The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)
Result source: NCT01392677
Ertugliflozin · Steglatro
Marketed by Merck & Co. and partners
NCT01986881 · Phase 3 · completed
This trial was randomized, double-blind, and placebo-controlled with over 8,000 participants, giving it strong statistical power, and its primary endpoint was a hard clinical composite (cardiovascular death, non-fatal MI, or non-fatal stroke) rather than a lab surrogate. The trial was designed as a cardiovascular-safety non-inferiority study, and the pre-specified margin was met, with the ertugliflozin-placebo hazard ratio's upper confidence bound (1.114) falling below the 1.3 non-inferiority threshold, demonstrating that ertugliflozin does not increase cardiovascular risk versus placebo in this population.
Next expected readout: January 2028 · NCT07621380 (registry estimate)
Reported efficacy
Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years); Baseline Hemoglobin A1C (A1C) (Insulin With or Without Metformin Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Insulin With or Without Metformin Add-on Glycemic Sub-study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Sulfonylurea Monotherapy Add-on Glycemic Sub-Study) (Baseline and Week 18); Baseline Hemoglobin A1C (A1C) (Metformin With Sulfonylurea Add-on Glycemic Sub-study); Change From Baseline in Hemoglobin A1C (A1C) at Week 18 - Excluding Rescue Approach (Metformin With Sulfonylurea Add-on Glycemic Sub-study) (Baseline and Week 18): Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years (met)
Result source: NCT01986881
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dapagliflozin | Ertugliflozin |
|---|---|---|
| HbA1c, change | -0.9% vs -0.2%−0.7 vs placeboNCT0052837250 other results
| -1.0% vs 0.2%−1.2 vs placeboNCT0195867165 other results
|
| Body weight, change (kg) | -3.2 vs -2.2−1 vs placeboNCT0052837240 other results
| -2.8 vs -0.4−2.4 vs placeboNCT0198688143 other results
|
| HbA1c below 7% | 50.8% vs 31.6%+19.2 vs placeboNCT0052837217 other results
| 28.2% vs 15.5%+12.7 vs placeboNCT0198688143 other results
|
| Fasting plasma glucose, change | -1.3 vs 0.2−1.5 vs placeboNCT0098486734 other results
| -1.9 vs -0.9−1 vs placeboNCT0198688163 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04170998 | —Not posted · NCT03717194 |
HbA1c, change
- Dapagliflozin
- -0.9% vs -0.2%−0.7 vs placeboNCT00528372
50 other results
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.2% NCT01392677
- -0.9% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.6% vs 0.1% NCT00357370
- -0.7% vs 0.1% NCT00357370
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.3% NCT00528879
- -0.8% vs -0.1% NCT00680745
- -1.0% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.8% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.6% vs 0.4% NCT03199053
- -0.5% vs 0.0% NCT00984867
- -1.2% vs -1.4% NCT00643851
- -2.0% vs -1.4% NCT00643851
- -0.5% vs -0.5% NCT00660907
- -2.0% vs -1.4% NCT00859898
- -1.4% vs -1.4% NCT00859898
- -0.9% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.7% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -2.0% vs 0.2% NCT00528372
- -1.2% vs 0.2% NCT00528372
- -1.4% vs -0.5% NCT00528879
- -0.8% vs 0.0% NCT00984867
- -2% vs 0.2% NCT00528372
- -1.5% vs 0.2% NCT00528372
- -1.3% vs 0.2% NCT00528372
- -1.4% vs 0.2% NCT00528372
- -1.3% vs -0.5% NCT00528879
- -1.2% vs -0.5% NCT00528879
- -1.7% vs -1.8% NCT00643851
- -3.0% vs -1.8% NCT00643851
- -2.6% vs -2.0% NCT00859898
- -2.1% vs -2.0% NCT00859898
- -1% vs -0.5% NCT02564926
- Ertugliflozin
- -1.0% vs 0.2%−1.2 vs placeboNCT01958671
65 other results
- -0.9% vs -0.0% NCT02033889
- -0.9% vs -0.1% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.9% vs -0.2% NCT02630706
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.2% NCT01986881
- -0.8% vs -0.6% NCT01986881
- -1.0% vs -0.2% NCT01986881
- -0.8% vs 0.2% NCT01958671
- -0.7% vs -0.0% NCT02033889
- -0.8% vs -0.1% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -1% vs -0.2% NCT02630706
- -0.9% vs -0.6% NCT01986881
- -0.9% vs -0.2% NCT01986881
- -1.7% vs -0.4% NCT02226003
- -1.6% vs -0.4% NCT02226003
- -0.6% vs 0.1% NCT04029480
- -0.6% vs -0.7% NCT01999218
- -1.1% vs -1.1% NCT02099110
- -0.6% vs -0.7% NCT01999218
- -1.0% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -1.5% vs -1.1% NCT02099110
- -0.7% vs -0.2% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.7% vs -0.2% NCT01986881
- -0.5% vs -0.1% NCT01986881
- -0.4% vs -0.0% NCT01986881
- -0.2% vs 0.1% NCT01986881
- -0.3% vs -0.1% NCT01986881
- -0.7% vs -0.7% NCT02033889
- -0.3% vs -0.1% NCT01986881
- -1.0% vs -0.7% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.4% vs -0.3% NCT01986855
- -0.9% vs -0.6% NCT02033889
- -0.8% vs 0.0% NCT02036515
- -0.3% vs -0.3% NCT01986855
- -0.5% vs 0.3% NCT04029480
- -0.6% vs -0.6% NCT02033889
- -0.2% vs 0.8% NCT04029480
- -0.4% vs 0.3% NCT04029480
- -0.1% vs 0.2% NCT01986881
- -0.3% vs 0.2% NCT01986881
- -0.8% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.3% vs 0% NCT01059825
- -0.8% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.7% vs -0.1% NCT01059825
- -0.5% vs -0.0% NCT01059825
- -0.2% vs 0% NCT01059825
- -0.6% vs -0.1% NCT01059825
- -0.4% vs -0.0% NCT01059825
- -0.1% vs 0% NCT01059825
Body weight, change (kg)
- Dapagliflozin
- -3.2 vs -2.2−1 vs placeboNCT00528372
40 other results
- -3.0 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -2.6 vs -0.6 NCT01392677
- -1.7 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -2.8 vs -2.2 NCT00528372
- -3.5 vs -2.2 NCT00528372
- -2.9 vs -2.4 NCT00528372
- -3.7 vs -2.4 NCT00528372
- -3.3 vs -2.2 NCT00528372
- -3.8 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -4.3 vs -2.4 NCT00528372
- -2.9 vs -0.9 NCT00528879
- -3.1 vs -1.0 NCT00528879
- -2.3 vs -0.7 NCT00680745
- -2.5 vs -0.8 NCT00680745
- -0.1 vs 1.6 NCT00683878
- -0.1 vs 1.8 NCT00683878
- -3.0 vs -0.9 NCT00528879
- -3.2 vs -1.0 NCT00528879
- -1.6 vs -0.7 NCT00680745
- -1.7 vs -0.8 NCT00680745
- 0.1 vs 1.6 NCT00683878
- 0.3 vs 1.8 NCT00683878
- -2.2 vs -0.9 NCT00528879
- -2.4 vs -1.0 NCT00528879
- -1.2 vs -0.7 NCT00680745
- -1.2 vs -0.8 NCT00680745
- -2.1 vs -0.3 NCT00984867
- -2.6 vs -1.3 NCT00643851
- -2.9 vs -1.5 NCT00643851
- -2.7 vs -1.3 NCT00643851
- -3.0 vs -1.5 NCT00643851
- -3.2 vs 1.4 NCT00660907
- -3.3 vs -1.4 NCT00859898
- -2.7 vs -1.4 NCT00859898
- -2.4 vs 1.3 NCT02564926
- Ertugliflozin
- -2.8 vs -0.4−2.4 vs placeboNCT01986881
43 other results
- -2.3 vs -0.4 NCT01986881
- -3.2 vs -0.7 NCT01986881
- -3.4 vs -1.0 NCT01986881
- -3.8 vs -1.3 NCT01986881
- -2.5 vs -0.4 NCT01986881
- -2.0 vs -0.4 NCT01986881
- -2.8 vs -0.7 NCT01986881
- -3.0 vs -1.0 NCT01986881
- -3.4 vs -1.3 NCT01986881
- -3.4 vs 0.1 NCT02033889
- -3.6 vs -1.4 NCT01958671
- -2.9 vs -1.3 NCT02033889
- -3.2 vs -1.2 NCT02630706
- -2.1 vs -0.3 NCT01986881
- -4.6 vs -1.2 NCT01986881
- -2.8 vs -0.9 NCT02036515
- -3.2 vs 0.1 NCT02033889
- -1.9 vs -0.3 NCT01986881
- -3.7 vs -1.2 NCT01986881
- -3.0 vs -1.3 NCT02036515
- -1.4 vs 0.5 NCT01986855
- -3.0 vs -1.2 NCT02630706
- -1.2 vs -0.7 NCT01986881
- -2.4 vs -0.5 NCT01986881
- -3.6 vs -0.2 NCT02033889
- -3.5 vs -0.9 NCT02036515
- -3.2 vs -1.4 NCT01958671
- -3.0 vs -1.3 NCT02033889
- -3.4 vs -1.3 NCT02036515
- -1.3 vs 0.5 NCT01986855
- -1.8 vs -0.7 NCT01986881
- -2.0 vs -0.5 NCT01986881
- -3.8 vs -0.2 NCT02033889
- -3.0 vs -0.9 NCT02226003
- -2.9 vs -0.9 NCT02226003
- -7.4 vs -1.0 NCT01986881
- -4.2 vs -1.0 NCT01986881
- -3.4 vs 0.9 NCT01999218
- -3.7 vs -0.7 NCT02099110
- -3.0 vs 0.9 NCT01999218
- -2.7 vs -0.7 NCT02099110
- -2.9 vs -0.7 NCT02099110
- -2.5 vs -0.7 NCT02099110
HbA1c below 7%
- Dapagliflozin
- 50.8% vs 31.6%+19.2 vs placeboNCT00528372
17 other results
- 51.6% vs 31.6% NCT00528372
- 31.8% vs 11.1% NCT01392677
- 44.2% vs 31.6% NCT00528372
- 44% vs 31.6% NCT00528372
- 41.3% vs 31.6% NCT00528372
- 51.4% vs 31.6% NCT00528372
- 40.6% vs 25.9% NCT00528879
- 31.7% vs 13% NCT00680745
- 38.8% vs 22.4% NCT00683878
- 37.5% vs 25.9% NCT00528879
- 30.3% vs 13% NCT00680745
- 32.5% vs 22.4% NCT00683878
- 33% vs 25.9% NCT00528879
- 26.8% vs 13% NCT00680745
- 26.6% vs 10% NCT03199053
- 22.5% vs 34.6% NCT00643851
- 52.4% vs 34.6% NCT00643851
- Ertugliflozin
- 28.2% vs 15.5%+12.7 vs placeboNCT01986881
43 other results
- 29% vs 17.4% NCT01986881
- 23.8% vs 16.6% NCT01986881
- 22.7% vs 16.9% NCT01986881
- 22.7% vs 18.2% NCT01986881
- 28.4% vs 15.5% NCT01986881
- 28.3% vs 17.4% NCT01986881
- 23.9% vs 16.6% NCT01986881
- 23.1% vs 16.9% NCT01986881
- 35.8% vs 13.1% NCT01958671
- 40% vs 15.8% NCT02033889
- 40.8% vs 16.2% NCT02630706
- 21.1% vs 10.7% NCT01986881
- 33.7% vs 19.1% NCT02033889
- 20% vs 16.5% NCT01986881
- 20.7% vs 10.7% NCT01986881
- 24.9% vs 18.2% NCT01986881
- 39.9% vs 17% NCT02036515
- 11.3% vs 12.1% NCT01986855
- 36.6% vs 30.6% NCT02033889
- 35.3% vs 15.8% NCT02033889
- 34.8% vs 30.6% NCT02033889
- 24.6% vs 19.1% NCT02033889
- 18.6% vs 16.5% NCT01986881
- 27.8% vs 25% NCT01986881
- 32.7% vs 12.8% NCT01986881
- 32.7% vs 13.7% NCT02036515
- 28.2% vs 13.1% NCT01958671
- 32.1% vs 17% NCT02036515
- 16.2% vs 12.1% NCT01986855
- 38.2% vs 16.2% NCT02630706
- 32.7% vs 25% NCT01986881
- 37% vs 12.8% NCT01986881
- 33.3% vs 13.7% NCT02036515
- 31.3% vs 8.3% NCT02226003
- 35.7% vs 8.3% NCT02226003
- 31.9% vs 32.8% NCT02099110
- 26.4% vs 32.8% NCT02099110
- 49.2% vs 32.8% NCT02099110
- 52.3% vs 32.8% NCT02099110
- 42.9% vs 15.6% NCT01059825
- 36.2% vs 15.6% NCT01059825
- 38.6% vs 15.6% NCT01059825
- 44% vs 15.6% NCT01059825
Fasting plasma glucose, change
- Dapagliflozin
- -1.3 vs 0.2−1.5 vs placeboNCT00984867
34 other results
- -1.6 vs -0.2 NCT00528372
- -1.6 vs -0.2 NCT00528372
- -1.9 vs -0.0 NCT01392677
- -1.2 vs 0.2 NCT00673231
- -1.0 vs 0.2 NCT00673231
- 0.1 vs 1.0 NCT00357370
- -0.9 vs -0.1 NCT00528372
- -0.7 vs 0.2 NCT00673231
- -1.1 vs -0.1 NCT00528372
- -0.5 vs 1.0 NCT00357370
- -1.3 vs -0.2 NCT00528372
- -1.5 vs -0.2 NCT00528372
- -0.9 vs -0.1 NCT00528372
- -1.0 vs -0.1 NCT00528372
- -0.8 vs -0.2 NCT00528372
- -1.4 vs -0.2 NCT00528372
- -0.2 vs -0.1 NCT00528372
- -1.6 vs -0.1 NCT00680745
- -0.8 vs -0.1 NCT00528372
- -1.3 vs -0.3 NCT00528879
- -1.6 vs -0.3 NCT00683878
- -0.9 vs 0.1 NCT00528879
- -1.2 vs -0.3 NCT00528879
- -1.2 vs -0.1 NCT00680745
- -1.4 vs -0.3 NCT00683878
- -0.7 vs 0.1 NCT00528879
- -1.0 vs -0.3 NCT00528879
- -0.9 vs -0.1 NCT00680745
- -0.3 vs 0.1 NCT00528879
- -0.6 vs 0.5 NCT03199053
- -2.3 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00859898
- -2.6 vs -1.9 NCT00859898
- Ertugliflozin
- -1.9 vs -0.9−1 vs placeboNCT01986881
63 other results
- -1.6 vs -0.5 NCT01986881
- -1.4 vs -0.2 NCT01986881
- -1.3 vs -0.2 NCT01986881
- -1.8 vs -0.9 NCT01986881
- -0.9 vs 0.2 NCT01986881
- -1.6 vs -0.5 NCT01986881
- -1.2 vs -0.2 NCT01986881
- -1.1 vs -0.2 NCT01986881
- -2.2 vs -0.1 NCT02033889
- -1.8 vs -0.4 NCT01986881
- -0.6 vs -0.3 NCT01986881
- -1.8 vs -0.1 NCT02036515
- -1.9 vs -0.7 NCT02033889
- -1.6 vs -0.6 NCT02033889
- -1.5 vs -0.1 NCT02033889
- -1.5 vs -0.4 NCT01986881
- -0.8 vs 0.2 NCT01986881
- -0.8 vs -0.3 NCT01986881
- -2.4 vs 0.0 NCT01958671
- -1.1 vs -0.3 NCT01986855
- -1.9 vs -0.4 NCT02630706
- -1.5 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.5 vs 0.2 NCT02036515
- -1.9 vs 0.0 NCT01958671
- -1.5 vs -0.1 NCT02036515
- -0.7 vs -0.3 NCT01986855
- -2.1 vs -0.4 NCT02630706
- -1.6 vs -0.8 NCT01986881
- -2.0 vs -0.3 NCT01986881
- -1.2 vs -0.7 NCT02033889
- -1.4 vs 0.2 NCT02036515
- -1.0 vs -0.6 NCT02033889
- -1.1 vs 0.5 NCT04029480
- -0.7 vs 1.2 NCT04029480
- -4.7 vs 0.8 NCT01986881
- -0.1 vs 0.8 NCT01986881
- -2.0 vs -1.4 NCT02099110
- -2.0 vs -1.4 NCT02099110
- -2.7 vs -1.4 NCT02099110
- -2.4 vs -1.4 NCT02099110
- -1.3 vs 0.1 NCT01059825
- -1.4 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.3 vs 0.3 NCT01059825
- -1.3 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.6 vs 0.1 NCT01059825
- -1.7 vs 0.2 NCT01059825
- -1.7 vs 0.2 NCT01096667
- -1.5 vs 0.3 NCT01059825
- -1.8 vs -0.3 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -1.8 vs 0.1 NCT01059825
- -1.8 vs 0.2 NCT01059825
- -1.6 vs 0.3 NCT01059825
- -1.5 vs 0.3 NCT01059825
- -1.0 vs 0.1 NCT01059825
- -1.0 vs 0.2 NCT01059825
- -0.8 vs 0.2 NCT01096667
- -0.9 vs 0.3 NCT01059825
- -0.6 vs -0.3 NCT01096667
- -0.8 vs 0.3 NCT01059825
3-point MACE (% with event)
- Dapagliflozin
- —Not posted · NCT04170998
- Ertugliflozin
- —Not posted · NCT03717194
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Dapagliflozin: 8 of 8 rows · Ertugliflozin: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapagliflozin Rows use multiple source trials | Ertugliflozin Rows use multiple source trials |
|---|---|---|
| DBP absolute change · mmHg | -0.25 vs 2.36 Glimepiride mmHg @ 52wka,b,c,d NCT02564926 · Phase 4 · registry result, not featured evidence | -0.97 vs 1.21 placebo mmHg @ 26wk15 mg + 100 mge,a,b,c,d NCT02226003 · Phase 3 · combination show 1 more dose-0.44 vs 1.21 placebo mmHg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| LVGLS absolute change · percentage points | 0.30769% (n=24) vs -0.00352% (n=24) placebo @ 6wk10 mga,f,c,g NCT03387683 · Phase 4 · registry result, not featured evidence | 16.6% (n=51) vs 16.4% (n=51) placebo @ 24wka,f,c,g NCT03717194 · Phase 3 · registry result, not featured evidence |
| SBP absolute change · mmHg | -2.18 vs 4.63 Glimepiride mmHg @ 52wka,b,c,d NCT02564926 · Phase 4 · registry result, not featured evidence | -3.98 vs 2.41 placebo mmHg @ 26wk15 mg + 100 mge,a,b,c,d NCT02226003 · Phase 3 · combination show 1 more dose-2.04 vs 2.41 placebo mmHg @ 26wk5 mg + 100 mg NCT02226003 · Phase 3 · combination |
| Seated SBP absolute change · mmHg | -4.04 vs -0.27 placebo mmHg @ 8wk10 mgb,h NCT01392677 · Phase 3 · combination 1 other source trial-5.98 vs -5.12 placebo mmHg @ 8wk NCT00984867 · Phase 3 | -3.46 vs 2.72 placebo mmHg @ 312wk15 mge,b,h NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 1 more dose1.28 vs 2.72 placebo mmHg @ 312wk5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 |
| Dropout rate | 18.6%10 mg AMi NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results14.5%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.8%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.8%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 16.2%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.7%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 13.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 0%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 14.2%Dapagliflozin NCT00859898 · Phase 3 13.3%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 16.3%5 mg NCT00643851 · Phase 3 8.8%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 11.9%10 mg NCT00528879 · Phase 3 · combination 10.9%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 12.4%2.5 mg NCT00528879 · Phase 3 · combination 20.7% NCT00660907 · Phase 3 · combination 6.6%10 mg NCT00680745 · Phase 3 · combination 9%5 mg NCT00680745 · Phase 3 · combination 9.1%2.5 mg NCT00680745 · Phase 3 · combination 7.3%10 mg NCT01392677 · Phase 3 · combination 10%10MG NCT00683878 · Phase 3 · combination 11.3%5MG NCT00683878 · Phase 3 · combination 7.6% NCT00984867 · Phase 3 9.2%10mg NCT00673231 · Phase 3 12.3%5mg NCT00673231 · Phase 3 10.9%2.5mg NCT00673231 · Phase 3 2.5%10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 6.2%Dapagliflozin NCT03199053 · Phase 3 · background therapy 1.3%10 mg NCT01730534 · Phase 3 16.7%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 16.7%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination 12.9% NCT03782259 · Phase 4 · registry result, not featured evidence 16% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence 7.4%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 7.7% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence 8.3% NCT03074630 · Phase 4 · registry result, not featured evidence 13.3% NCT02564926 · Phase 4 · registry result, not featured evidence | —15 mgi NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.6%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15.8%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.2%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 22.9%15 mg NCT01999218 · Phase 3 24.3%5 mg NCT01999218 · Phase 3 12.5%15 mg NCT02099110 · Phase 3 9.6%5 mg NCT02099110 · Phase 3 11%15 mg + 100 mg NCT02099110 · Phase 3 · combination 9.1%5 mg + 100 mg NCT02099110 · Phase 3 · combination 7.7%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 3.2%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination 1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 9%15 mg NCT01986855 · Phase 3 8.2%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.3%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 4.1%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 0% NCT03416270 · Phase 2 · registry result, not featured evidence 5.3%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 7.7%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 5.1%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 39.3% NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 8.6%10 mg AMi NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 4.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 —20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.1%Dapagliflozin NCT00859898 · Phase 3 1.9%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 3%5 mg NCT00643851 · Phase 3 1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 3%10 mg NCT00528879 · Phase 3 · combination 1.5%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 2.9%2.5 mg NCT00528879 · Phase 3 · combination 8.1% NCT00660907 · Phase 3 · combination 2%10 mg NCT00680745 · Phase 3 · combination 2.1%5 mg NCT00680745 · Phase 3 · combination 3.2%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 2.1%10MG NCT00683878 · Phase 3 · combination 2.1%5MG NCT00683878 · Phase 3 · combination 3.1% NCT00984867 · Phase 3 3.1%10mg NCT00673231 · Phase 3 4.2%5mg NCT00673231 · Phase 3 2.5%2.5mg NCT00673231 · Phase 3 —10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy —10 mg NCT01730534 · Phase 3 —Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence —T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence —Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence —Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 4% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence —10 mg NCT03387683 · Phase 4 · registry result, not featured evidence — NCT02433678 · Phase 4 · registry result, not featured evidence —10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence — NCT02564926 · Phase 4 · registry result, not featured evidence | —15 mgi NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results—15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.7%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.6%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%15 mg NCT02033889 · Phase 3 0.5%5 mg NCT02033889 · Phase 3 1.6%15 mg NCT01999218 · Phase 3 2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 1.2%5 mg NCT02099110 · Phase 3 0.8%15 mg + 100 mg NCT02099110 · Phase 3 · combination 1.2%5 mg + 100 mg NCT02099110 · Phase 3 · combination 0.6%15 mg NCT02036515 · Phase 3 —15 mg NCT02036515 · Phase 3 · combination 0.6%5 mg NCT02036515 · Phase 3 —5 mg NCT02036515 · Phase 3 · combination —15 mg + 100 mg NCT02226003 · Phase 3 · combination —5 mg + 100 mg NCT02226003 · Phase 3 · combination 0%15 mg NCT01986855 · Phase 3 0.6%5 mg NCT01986855 · Phase 3 —15 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence —5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0.6%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 1.2%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence — NCT03416270 · Phase 2 · registry result, not featured evidence —5 mg NCT01096667 · Phase 2 · registry result, not featured evidence —25 mg NCT01096667 · Phase 2 · registry result, not featured evidence —1 mg NCT01096667 · Phase 2 · registry result, not featured evidence —5 mg NCT01059825 · Phase 2 · registry result, not featured evidence —25 mg NCT01059825 · Phase 2 · registry result, not featured evidence —10 mg NCT01059825 · Phase 2 · registry result, not featured evidence —1 mg NCT01059825 · Phase 2 · registry result, not featured evidence — NCT04167761 · Phase 1 · registry result, not featured evidence —15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence —2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence —1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 1.4%10 mg AMi NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 7.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.2%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 2.3%Dapagliflozin NCT00859898 · Phase 3 1.4%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 4.4%5 mg NCT00643851 · Phase 3 3.1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 10.4%10 mg NCT00528879 · Phase 3 · combination —5 mg NCT00528879 · Phase 3 · combination 6.6%5.0 mg NCT00528879 · Phase 3 · combination 10.9%2.5 mg NCT00528879 · Phase 3 · combination 8.6% NCT00660907 · Phase 3 · combination 6%10 mg NCT00680745 · Phase 3 · combination 6.9%5 mg NCT00680745 · Phase 3 · combination 7.1%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 1.4%10MG NCT00683878 · Phase 3 · combination 2.8%5MG NCT00683878 · Phase 3 · combination 4.4% NCT00984867 · Phase 3 7.1%10mg NCT00673231 · Phase 3 4.7%5mg NCT00673231 · Phase 3 7.4%2.5mg NCT00673231 · Phase 3 5.6%10mg QD NCT02413398 · Phase 3 0%10 mg NCT03199053 · Phase 3 4.8%10 mg NCT03199053 · Phase 3 0%10 mg NCT03199053 · Phase 3 · combination 1.2%5 mg NCT03199053 · Phase 3 0%5 mg NCT03199053 · Phase 3 9.1%5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy 37.4%10 mg NCT01730534 · Phase 3 0%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 0% NCT02235298 · Phase 4 · registry result, not featured evidence 0% NCT02796170 · Phase 4 · registry result, not featured evidence 0%10mg NCT03338855 · Phase 4 · registry result, not featured evidence 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 0%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 0% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence 10% NCT02564926 · Phase 4 · registry result, not featured evidence | 7.3%15 mgi NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results7.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.1%15 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.9%15 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 9.5%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 34.9%5 mg NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.3%5 mg NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.9%15 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.1%5 mg NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.8%15 mg NCT02033889 · Phase 3 9.7%5 mg NCT02033889 · Phase 3 7.4%15 mg NCT01999218 · Phase 3 9.2%5 mg NCT01999218 · Phase 3 2%15 mg NCT02099110 · Phase 3 4.8%5 mg NCT02099110 · Phase 3 4.9%15 mg + 100 mg NCT02099110 · Phase 3 · combination 3.7%5 mg + 100 mg NCT02099110 · Phase 3 · combination —15 mg NCT02036515 · Phase 3 2%15 mg NCT02036515 · Phase 3 · combination —5 mg NCT02036515 · Phase 3 8.3%5 mg NCT02036515 · Phase 3 · combination 3.1%15 mg + 100 mg NCT02226003 · Phase 3 · combination 2%5 mg + 100 mg NCT02226003 · Phase 3 · combination 19.4%15 mg NCT01986855 · Phase 3 16.5%5 mg NCT01986855 · Phase 3 3.8%15 mg NCT04029480 · Phase 3 · registry result, not featured evidence 3.2%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 0%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 4.5%5 mg NCT04029480 · Phase 3 · registry result, not featured evidence 5.9%15 mg NCT02630706 · Phase 3 · registry result, not featured evidence 5.3%5 mg NCT02630706 · Phase 3 · registry result, not featured evidence 17.6% NCT03416270 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%25 mg NCT01096667 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01096667 · Phase 2 · registry result, not featured evidence 3.6%5 mg NCT01059825 · Phase 2 · registry result, not featured evidence 1.8%25 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%10 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0%1 mg NCT01059825 · Phase 2 · registry result, not featured evidence 0% NCT04167761 · Phase 1 · registry result, not featured evidence 0%15 mg Oral + 100 ug Oral NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg Oral + 100 ug IV NCT02411929 · Phase 1 · registry result, not featured evidence · combination 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence 0%15 mg NCT02115347 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence —15 mg NCT01948986 · Phase 1 · registry result, not featured evidence 0%4 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Once Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%2 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence 0%1 mg Twice Daily NCT01054300 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mg AMi nasopharyngitis 14.3% (placebo 9.3%) arthralgia 8.6% (placebo 4%) headache 8.6% (placebo 12%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 42 more results10 mg PM headache 13.2% (placebo 12%) upper respiratory tract infection 11.8% (placebo 5.3%) back pain 9.2% (placebo 6.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg AM pharyngitis 9.4% (placebo 8%) arthralgia 7.8% (placebo 4%) headache 7.8% (placebo 12%) NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 5 mg PM headache 16.2% (placebo 12%) nasopharyngitis 13.2% (placebo 9.3%) arthralgia 11.8% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg AM nasopharyngitis 16.9% (placebo 9.3%) influenza 10.8% (placebo 4%) arthralgia 9.2% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg PM nasopharyngitis 16.4% (placebo 9.3%) abdominal pain 9% (placebo 2.7%) dizziness 9% (placebo 2.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg back pain 12.5% (placebo 8.7%) headache 12.5% (placebo 8.7%) fatigue 8.3% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 20 mg nausea 12.5% (placebo 4.3%) pollakiuria 12.5% (placebo 17.4%) vomiting 12.5% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 diarrhoea 7.1% vulvovaginal mycotic infection 3.3% urinary tract infection 2.8% NCT00859898 · Phase 3 · combination 5 mg dyslipidaemia 5.4% upper respiratory tract infection 4.9% urinary tract infection 4.4% NCT00643851 · Phase 3 10 mg back pain 13.3% (placebo 8%) influenza 12.6% (placebo 10.9%) diarrhoea 11.9% (placebo 7.3%) NCT00528879 · Phase 3 · combination 5.0 mg influenza 14.6% (placebo 10.9%) headache 9.5% (placebo 5.8%) arthralgia 7.3% (placebo 5.1%) NCT00528879 · Phase 3 · combination 2.5 mg influenza 13.9% (placebo 10.9%) nasopharyngitis 11.7% (placebo 8.8%) back pain 8% (placebo 8%) NCT00528879 · Phase 3 · combination 10 mg hypoglycemia 7.9% (placebo 4.8%) nasopharyngitis 3.3% (placebo 2.7%) hypertension 1.3% (placebo 4.1%) NCT00680745 · Phase 3 · combination 5 mg hypoglycemia 6.9% (placebo 4.8%) nasopharyngitis 5.5% (placebo 2.7%) hypertension 1.4% (placebo 4.1%) NCT00680745 · Phase 3 · combination 2.5 mg hypoglycemia 7.1% (placebo 4.8%) hypertension 5.2% (placebo 4.1%) nasopharyngitis 1.9% (placebo 2.7%) NCT00680745 · Phase 3 · combination 10MG dyslipidaemia 9.3% (placebo 4.3%) nasopharyngitis 7.9% (placebo 3.6%) diarrhoea 6.4% (placebo 4.3%) NCT00683878 · Phase 3 · combination 5MG upper respiratory tract infection 6.4% (placebo 5.8%) dyslipidaemia 5.7% (placebo 4.3%) nasopharyngitis 5% (placebo 3.6%) NCT00683878 · Phase 3 · combination nasopharyngitis 4% (placebo 6.2%) NCT00984867 · Phase 3 10mg hypoglycemia 44.9% (placebo 42.1%) nasopharyngitis 8.7% (placebo 11.2%) urinary tract infection 5.6% (placebo 3%) NCT00673231 · Phase 3 5mg hypoglycemia 47.6% (placebo 42.1%) nasopharyngitis 13.7% (placebo 11.2%) hypertension 6.1% (placebo 8.1%) NCT00673231 · Phase 3 2.5mg hypoglycemia 55% (placebo 42.1%) nasopharyngitis 13.9% (placebo 11.2%) hypertension 5.4% (placebo 8.1%) NCT00673231 · Phase 3 10 mg abdominal pain 4.8% (placebo 2.6%) abdominal pain upper 4.8% (placebo 0%) bronchitis 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg dysmenorrhoea 9.5% (placebo 2.6%) headache 9.5% (placebo 1.3%) conjunctivitis allergic 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg pharyngotonsillitis 14.3% (placebo 1.3%) tonsillitis 14.3% (placebo 0%) abdominal pain 0% (placebo 2.6%) NCT03199053 · Phase 3 · combination 5 mg headache 7.4% (placebo 1.3%) hypertriglyceridaemia 4.9% (placebo 1.3%) diarrhoea 3.7% (placebo 3.9%) NCT03199053 · Phase 3 5 mg headache 9.1% (placebo 1.3%) nasopharyngitis 3.6% (placebo 2.6%) anxiety 1.8% (placebo 0%) NCT03199053 · Phase 3 5 mg influenza 5.5% (placebo 2.6%) abdominal pain upper 3.6% (placebo 0%) headache 3.6% (placebo 1.3%) NCT03199053 · Phase 3 10 mg renal impairment 1.4% (placebo 1.7%) acute kidney injury 1% (placebo 1.3%) chronic kidney disease 0.9% (placebo 1.2%) NCT01730534 · Phase 3 genital mycotic infection 13.3% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence genital mycotic infection 26.7% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence transcient syncope 12.5% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence transcient syncope 0% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence nausea and vomiting 24% (placebo 0%) genital mycosis 0% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence nausea and vomiting 20% (placebo 0%) genital mycosis 8% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence · combination dysuria 12% (placebo 0%) frequency of urination 12% (placebo 0%) balanitis 2% (placebo 0%) NCT02235298 · Phase 4 · registry result, not featured evidence cold like symptoms 4.5% genital yeast infection 4.5% abrasion of left cornea 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 10mg Once Daily genital fungal infections 20.8% NCT02682563 · Phase 4 · registry result, not featured evidence nasopharyngitis 6.7% toothache 6.7% hypoglycaemia 5% NCT02564926 · Phase 4 · registry result, not featured evidence | 15 mgi hypoglycaemia 30.3% (placebo 31.4%) nasopharyngitis 3.5% (placebo 3.2%) upper respiratory tract infection 2.7% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 44 more results15 mg hypoglycaemia 16.8% (placebo 31.4%) nasopharyngitis 4.4% (placebo 3.2%) dizziness 3.5% (placebo 1.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 31.1% (placebo 31.4%) urinary tract infection 9.5% (placebo 2%) nasopharyngitis 7.4% (placebo 3.2%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg hypoglycaemia 5.6% (placebo 31.4%) urinary tract infection 1.9% (placebo 2%) back pain 0% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 29% (placebo 31.4%) dizziness 2.3% (placebo 1.2%) upper respiratory tract infection 2.3% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 13% (placebo 31.4%) hypertension 4% (placebo 0.6%) hyperglycaemia 3% (placebo 1.7%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 32.2% (placebo 31.4%) urinary tract infection 9.3% (placebo 2%) upper respiratory tract infection 7.2% (placebo 2.6%) NCT01986881 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg hypoglycaemia 5.5% (placebo 31.4%) back pain 3.6% (placebo 0.6%) hypertension 3.6% (placebo 0.6%) NCT01986881 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 15 mg nasopharyngitis 7.2% (placebo 3.9%) upper respiratory tract infection 6.6% (placebo 5.9%) urinary tract infection 6.6% (placebo 12.4%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg urinary tract infection 8.3% (placebo 12.4%) vulvovaginal mycotic infection 7.7% (placebo 1.3%) constipation 7.1% (placebo 2.6%) NCT01958671 · Phase 3 · combination · Type 2 Diabetes · phase 3 15 mg upper respiratory tract infection 10.2% (placebo 15.8%) back pain 9.8% (placebo 4.8%) hypoglycaemia 8.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 11.1% (placebo 15.8%) headache 6.8% (placebo 4.8%) hypoglycaemia 6.8% (placebo 20.6%) NCT02033889 · Phase 3 5 mg upper respiratory tract infection 6.1% urinary tract infection 6.1% headache 5.6% NCT01999218 · Phase 3 15 mg + 100 mg hypoglycaemia 8.2% nasopharyngitis 4.9% urinary tract infection 3.3% NCT02099110 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.8% nasopharyngitis 4.9% hypoglycaemia 3.7% NCT02099110 · Phase 3 · combination 15 mg nasopharyngitis 3.9% (placebo 3.3%) hypoglycaemia 3.3% (placebo 7.2%) urinary tract infection 3.3% (placebo 5.2%) NCT02036515 · Phase 3 · combination 5 mg back pain 5.1% (placebo 3.9%) nasopharyngitis 5.1% (placebo 3.3%) hypoglycaemia 4.5% (placebo 7.2%) NCT02036515 · Phase 3 · combination 15 mg + 100 mg urinary tract infection 2.1% (placebo 1%) hyperglycaemia 1% (placebo 6.2%) blood glucose increased 0% (placebo 7.2%) NCT02226003 · Phase 3 · combination 5 mg + 100 mg urinary tract infection 5.1% (placebo 1%) blood glucose increased 3.1% (placebo 7.2%) hyperglycaemia 0% (placebo 6.2%) NCT02226003 · Phase 3 · combination 15 mg hypoglycaemia 20.6% (placebo 29.2%) urinary tract infection 7.7% (placebo 9.7%) upper respiratory tract infection 7.1% (placebo 4.5%) NCT01986855 · Phase 3 5 mg hypoglycaemia 31% (placebo 29.2%) diarrhoea 6.3% (placebo 5.8%) cough 5.7% (placebo 1.3%) NCT01986855 · Phase 3 15 mg hypoglycaemia 19.2% (placebo 12.7%) nausea 15.4% (placebo 7.3%) vomiting 15.4% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 14.3% (placebo 10.9%) hypoglycaemia 11.1% (placebo 12.7%) covid-19 7.9% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg hypoglycaemia 11.5% (placebo 12.7%) nausea 7.7% (placebo 7.3%) vomiting 7.7% (placebo 5.5%) NCT04029480 · Phase 3 · registry result, not featured evidence 5 mg nausea 13.6% (placebo 7.3%) abdominal pain 9.1% (placebo 5.5%) diarrhoea 9.1% (placebo 7.3%) NCT04029480 · Phase 3 · registry result, not featured evidence 15 mg hyperuricaemia 5.3% (placebo 12%) hypoglycaemia 5.3% (placebo 1.2%) nasopharyngitis 5.3% (placebo 6.6%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 5.3% (placebo 6.6%) hypoglycaemia 3.5% (placebo 1.2%) hyperuricaemia 2.9% (placebo 12%) NCT02630706 · Phase 3 · registry result, not featured evidence 5 mg genital infection fungal 7.9% (placebo 0%) athralgia 5.3% (placebo 0%) nasopharyngitis 5.3% (placebo 0%) NCT01096667 · Phase 2 · registry result, not featured evidence 25 mg fatigue 5.1% (placebo 0%) polyuria 5.1% (placebo 0%) dizziness 2.6% (placebo 5.3%) NCT01096667 · Phase 2 · registry result, not featured evidence 1 mg musculoskeletal pain 5.1% (placebo 0%) upper respiratory tract infection 2.6% (placebo 5.3%) urinary tract infection 2.6% (placebo 2.6%) NCT01096667 · Phase 2 · registry result, not featured evidence 5 mg arthralgia 10.9% (placebo 1.9%) headache 7.3% (placebo 3.7%) hypoglycaemia 5.5% (placebo 0%) NCT01059825 · Phase 2 · registry result, not featured evidence 25 mg genital infection fungal 7.3% (placebo 1.9%) diarrhoea 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 10 mg urinary tract infection 9.1% (placebo 7.4%) genital infection fungal 5.5% (placebo 1.9%) upper respiratory tract infection 5.5% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 1 mg arthralgia 3.7% (placebo 1.9%) diarrhoea 3.7% (placebo 1.9%) upper respiratory tract infection 3.7% (placebo 3.7%) NCT01059825 · Phase 2 · registry result, not featured evidence 15 mg Oral + 100 ug Oral nasal congestion 12.5% back pain 0% headache 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg Oral + 100 ug IV headache 25% back pain 12.5% nasal congestion 0% NCT02411929 · Phase 1 · registry result, not featured evidence · combination 15 mg decreased appetite 12.5% headache 12.5% tachycardia 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 15 mg arthralgia 12.5% back pain 12.5% dizziness 12.5% NCT02115347 · Phase 1 · registry result, not featured evidence 4 mg Once Daily diarrhoea 11.5% headache 7.7% abdominal pain 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Once Daily headache 11.5% constipation 3.8% dizziness 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 2 mg Twice Daily abdominal pain 3.8% diarrhoea 3.8% dry mouth 3.8% NCT01054300 · Phase 1 · registry result, not featured evidence 1 mg Twice Daily headache 12% back pain 4% dyspepsia 4% NCT01054300 · Phase 1 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 26 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fPopulation context differs: registered conditions differ.
- gAssessment timepoints differ: 6 weeks versus 24 weeks.
- hAssessment timepoints differ: 8 weeks versus 312 weeks.
- iPopulation comparability has not been reviewed for 44 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapagliflozin
show 5 more results
show 1 more result
show 8 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 1 more result
show 2 more results
show 2 more results
+ 33 further endpoints in the CSV export.
Ertugliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 23 more results
show 32 more results
show 13 more results
show 13 more results
show 11 more results
show 1 more result
show 11 more results
show 1 more result
+ 23 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · Ertugliflozin's landscape